{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:20:45Z","timestamp":1785540045202,"version":"3.56.0"},"reference-count":113,"publisher":"Walter de Gruyter GmbH","issue":"2-3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nephropathy and nephrotoxicity are significant causes of renal impairment, with both conditions contributing to a substantial global healthcare burden. Nephropathy encompasses a range of kidney diseases, including glomerulonephritis, diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease, each with distinct pathophysiological mechanisms and clinical manifestations. Nephrotoxicity, often induced by environmental toxins or medications, can lead to acute kidney injury (AKI) or chronic kidney disease (CKD) if not properly managed. Understanding the underlying processes and risk factors for kidney damage is crucial to preventing and treating these conditions effectively. However, while considerable research exists on each of these topics, there remains a gap in integrated knowledge regarding the diverse pathophysiological pathways, the role of early detection, and the optimal management strategies for nephropathy and nephrotoxicity. While substantial research has been conducted on nephropathy and nephrotoxicity, there remains a year gap in fully understanding the diverse mechanisms of kidney damage across different etiologies and\u00a0their long-term implications for renal health. This work aimed to fill this gap by synthesizing current research on the pathophysiology, clinical manifestations, and treatment approaches for both nephropathy and nephrotoxicity. Major findings highlight the importance of early detection through biomarkers, the need for vigilant monitoring of renal function, and the role of avoiding nephrotoxic agents in both medical and environmental contexts. The paper also emphasizes the critical role of individualized treatment approaches, including the careful use of medications to prevent drug-induced nephropathy.<\/jats:p>","DOI":"10.1515\/jbcpp-2024-0220","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:40:34Z","timestamp":1739832034000},"page":"69-93","source":"Crossref","is-referenced-by-count":11,"title":["Navigating nephropathy and nephrotoxicity: understanding pathophysiology unveiling clinical manifestations, and exploring treatment approaches"],"prefix":"10.1515","volume":"36","author":[{"given":"Aysha","family":"Javed","sequence":"first","affiliation":[{"name":"Department of Pharmacy , 93132 Integral University , Lucknow , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarique","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , 93132 Integral University , Lucknow , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshu","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , 93132 Integral University , Lucknow , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farogh","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , 93132 Integral University , Lucknow , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaseem Ahamad","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , 93132 Integral University , Lucknow , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzadi","family":"Bano","sequence":"additional","affiliation":[{"name":"Department of Chemistry , 93132 Integral University , Lucknow , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Masih","family":"Uzzam Khan","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmacognosy , College of Pharmacy, Qassim University , Buraydah , Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , 93132 Integral University , Lucknow , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_001","doi-asserted-by":"crossref","unstructured":"Matthaiou, A, Poulli, T, Deltas, C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J 2020;13:1025\u201336. https:\/\/doi.org\/10.1093\/ckj\/sfz176.","DOI":"10.1093\/ckj\/sfz176"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_002","doi-asserted-by":"crossref","unstructured":"El Nahas, AM, Bello, AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(05)17789-7.","DOI":"10.1016\/S0140-6736(05)17789-7"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_003","doi-asserted-by":"crossref","unstructured":"Kalantar-Zadeh, K, Jafar, TH, Nitsch, D, Neuen, BL, Perkovic, V. Chronic kidney disease. Lancet 2021;398:786\u2013802. https:\/\/doi.org\/10.1016\/s0140-6736(21)00519-5.","DOI":"10.1016\/S0140-6736(21)00519-5"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_004","doi-asserted-by":"crossref","unstructured":"Ortiz, A, Covic, A, Fliser, D, Fouque, D, Goldsmith, D, Kanbay, M, et al.. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014;383:1831\u201343. https:\/\/doi.org\/10.1016\/s0140-6736(14)60384-6.","DOI":"10.1016\/S0140-6736(14)60384-6"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_005","doi-asserted-by":"crossref","unstructured":"Eckardt, KU, Coresh, J, Devuyst, O, Johnson, RJ, K\u00f6ttgen, A, Levey, AS, et al.. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013;382:158\u201369. https:\/\/doi.org\/10.1016\/s0140-6736(13)60439-0.","DOI":"10.1016\/S0140-6736(13)60439-0"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_006","doi-asserted-by":"crossref","unstructured":"Saadat-Gilani, K, Zarbock, A. Perioperative renal protection. Curr Opin Crit Care 2021;27:676\u201385. https:\/\/doi.org\/10.1097\/mcc.0000000000000881.","DOI":"10.1097\/MCC.0000000000000881"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_007","doi-asserted-by":"crossref","unstructured":"Inker, LA, Astor, BC, Fox, CH, Isakova, T, Lash, JP, Peralta, CA, et al.. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713\u201335. https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.416.","DOI":"10.1053\/j.ajkd.2014.01.416"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_008","doi-asserted-by":"crossref","unstructured":"Akhtar, J, Ahmad, U, Badruddeen, I, Khan, M, editors. Metformin\u00a0\u2013 Pharmacology and Drug Interactions. IntechOpen; 2021. https:\/\/www.intechopen.com\/books\/metformin-pharmacology-and-drug-interactions [Accessed 6 Feb 2024].","DOI":"10.5772\/intechopen.94707"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_009","doi-asserted-by":"crossref","unstructured":"Ritz, E, Orth, SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127\u201333. https:\/\/doi.org\/10.1056\/nejm199910073411506.","DOI":"10.1056\/NEJM199910073411506"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_010","doi-asserted-by":"crossref","unstructured":"Reutens, AT, Atkins, RC. Epidemiology of diabetic nephropathy. In: Lai, KN, Tang, SCW, editors. Contributions to Nephrology. S. Karger AG; 2011:1\u20137 pp. Available from: https:\/\/www.karger.com\/Article\/FullText\/324934.","DOI":"10.1159\/000324934"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_011","doi-asserted-by":"crossref","unstructured":"Thomas, MC, Cooper, ME. Bardoxolone improves kidney function in type 2 diabetes. Nat Rev Nephrol 2011;7:552\u20133. https:\/\/doi.org\/10.1038\/nrneph.2011.114.","DOI":"10.1038\/nrneph.2011.114"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_012","doi-asserted-by":"crossref","unstructured":"Coresh, J, Astor, BC, Greene, T, Eknoyan, G, Levey, AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 2003;41:1\u201312. https:\/\/doi.org\/10.1053\/ajkd.2003.50007.","DOI":"10.1053\/ajkd.2003.50007"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_013","doi-asserted-by":"crossref","unstructured":"Dabla, PK. Renal function in diabetic nephropathy. World J Diabetes 2010;1:48. https:\/\/doi.org\/10.4239\/wjd.v1.i2.48.","DOI":"10.4239\/wjd.v1.i2.48"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_014","doi-asserted-by":"crossref","unstructured":"Gale, EA. Is there really an epidemic of type 2 diabetes? Lancet 2003;362:503\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(03)14148-7.","DOI":"10.1016\/S0140-6736(03)14148-7"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_015","doi-asserted-by":"crossref","unstructured":"Webster, AC, Nagler, EV, Morton, RL, Masson, P. Chronic kidney disease. Lancet 2017;389:1238\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(16)32064-5.","DOI":"10.1016\/S0140-6736(16)32064-5"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_016","doi-asserted-by":"crossref","unstructured":"Rossing, P, Persson, F, Frimodt-M\u00f8ller, M. Prognosis and treatment of diabetic nephropathy: recent advances and perspectives. N\u00e9phrol Th\u00e9rapeutique 2018;14:S31\u20137. https:\/\/doi.org\/10.1016\/j.nephro.2018.02.007.","DOI":"10.1016\/j.nephro.2018.02.007"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_017","doi-asserted-by":"crossref","unstructured":"G\u00e6de, P, Vedel, P, Larsen, N, Jensen, GVH, Parving, HH, Pedersen, O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383\u201393. https:\/\/doi.org\/10.1056\/nejmoa021778.","DOI":"10.1056\/NEJMoa021778"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_018","doi-asserted-by":"crossref","unstructured":"Fioretto, P, Steffes, MW, Sutherland, DER, Goetz, FC, Mauer, M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69\u201375. https:\/\/doi.org\/10.1056\/nejm199807093390202.","DOI":"10.1056\/NEJM199807093390202"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_019","doi-asserted-by":"crossref","unstructured":"Cortinovis, M, Cattaneo, D, Perico, N, Remuzzi, G. Investigational drugs for diabetic nephropathy. Expet Opin Invest Drugs 2008;17:1487\u2013500. https:\/\/doi.org\/10.1517\/13543784.17.10.1487.","DOI":"10.1517\/13543784.17.10.1487"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_020","doi-asserted-by":"crossref","unstructured":"Telmisartan, R. Or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547\u201359.","DOI":"10.1056\/NEJMoa0801317"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_021","doi-asserted-by":"crossref","unstructured":"Nathan, DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342\u20139. https:\/\/doi.org\/10.1056\/nejmcp021106.","DOI":"10.1056\/NEJMcp021106"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_022","doi-asserted-by":"crossref","unstructured":"Remuzzi, G, Benigni, A. Endothelins in the control of cardiovascular and renal function. Lancet 1993;342:589\u201393. https:\/\/doi.org\/10.1016\/0140-6736(93)91414-h.","DOI":"10.1016\/0140-6736(93)91414-H"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_023","doi-asserted-by":"crossref","unstructured":"Hargrove, GM, Dufresne, J, Whiteside, C, Muruve, DA, Wong, NCW. Diabetes mellitus increases endothelin-1 gene transcription in rat kidney. Kidney Int 2000;58:1534\u201345. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00315.x.","DOI":"10.1046\/j.1523-1755.2000.00315.x"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_024","doi-asserted-by":"crossref","unstructured":"Mancia, G, Fagard, R, Narkiewicz, K, Red\u00f3n, J, Zanchetti, A, B\u00f6hm, M, et al.. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the\u00a0European Society of Cardiology (ESC). J Hypertens 2013;31:1281\u2013357. https:\/\/doi.org\/10.1097\/01.hjh.0000431740.32696.cc.","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_025","doi-asserted-by":"crossref","unstructured":"Udani, S, Lazich, I, Bakris, GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011;7:11\u201321. https:\/\/doi.org\/10.1038\/nrneph.2010.154.","DOI":"10.1038\/nrneph.2010.154"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_026","doi-asserted-by":"crossref","unstructured":"Dasgupta, I, Porter, C, Innes, A, Burden, R. \u201cBenign\u201d hypertensive nephrosclerosis. QJM 2006;100:113\u20139. https:\/\/doi.org\/10.1093\/qjmed\/hcl139.","DOI":"10.1093\/qjmed\/hcl139"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_027","doi-asserted-by":"crossref","unstructured":"Manvi, Khan, MI, Badruddeen, Akhtar, J, Ahmad, M, Siddiqui, Z, et al.. Role of plant bioactive as diuretics: general considerations and mechanismof diuresis. Curr Hypertens Rev 2023;19:79\u201392. https:\/\/doi.org\/10.2174\/1573402119666230612115220.","DOI":"10.2174\/1573402119666230612115220"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_028","doi-asserted-by":"crossref","unstructured":"Sabbisetti, VS, Waikar, SS, Antoine, DJ, Smiles, A, Wang, C, Ravisankar, A, et al.. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 2014;25:2177\u201386. https:\/\/doi.org\/10.1681\/asn.2013070758.","DOI":"10.1681\/ASN.2013070758"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_029","doi-asserted-by":"crossref","unstructured":"Seccia, TM, Caroccia, B, Gioco, F, Piazza, M, Buccella, V, Guidolin, D, et al.. Endothelin\u20101 drives epithelial\u2010mesenchymal transition in hypertensive nephroangiosclerosis. J Am Heart Assoc 2016;5:e003888. https:\/\/doi.org\/10.1161\/jaha.116.003888.","DOI":"10.1161\/JAHA.116.003888"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_030","doi-asserted-by":"crossref","unstructured":"Grisk, O. Interactions between the sympathetic nervous system and the kidneys in arterial hypertension. Cardiovasc Res 2004;61:238\u201346. https:\/\/doi.org\/10.1016\/j.cardiores.2003.11.024.","DOI":"10.1016\/j.cardiores.2003.11.024"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_031","doi-asserted-by":"crossref","unstructured":"Freedman, BI, Sedor, JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008;19:2047\u201351. https:\/\/doi.org\/10.1681\/asn.2008060621.","DOI":"10.1681\/ASN.2008060621"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_032","doi-asserted-by":"crossref","unstructured":"Garg, JP, Ellis, R, Elliott, WJ, Hasabou, N, Chua, D, Chertow, GM, et al.. Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol 2005;25:393\u20139. https:\/\/doi.org\/10.1159\/000087211.","DOI":"10.1159\/000087211"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_033","doi-asserted-by":"crossref","unstructured":"Offurum, A, Wagner, LA, Gooden, T. Adverse safety events in patients with chronic kidney disease (CKD). Expet Opin Drug Saf 2016;15:1597\u2013607. https:\/\/doi.org\/10.1080\/14740338.2016.1236909.","DOI":"10.1080\/14740338.2016.1236909"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_034","doi-asserted-by":"crossref","unstructured":"Mishra, SI, Jones-Burton, C, Fink, JC, Brown, J, Bakris, GL, Weir, MR. Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep 2005;7:385\u201391. https:\/\/doi.org\/10.1007\/s11906-005-0076-2.","DOI":"10.1007\/s11906-005-0076-2"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_035","doi-asserted-by":"crossref","unstructured":"Lewis, EJ, Hunsicker, LG, Clarke, WR, Berl, T, Pohl, MA, Lewis, JB, et al.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851\u201360. https:\/\/doi.org\/10.1056\/nejmoa011303.","DOI":"10.1056\/NEJMoa011303"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_036","doi-asserted-by":"crossref","unstructured":"Zuber, K, Gilmartin, C, Davis, J. Managing hypertension in patients with chronic kidney disease. J Am Acad Phys Assis 2014;27:37\u201346. https:\/\/doi.org\/10.1097\/01.jaa.0000453239.92473.41.","DOI":"10.1097\/01.JAA.0000453239.92473.41"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_037","doi-asserted-by":"crossref","unstructured":"Matthews, KA, Brenner, MJ, Brenner, AC. Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. Clin Ther 2013;35:1423\u201330. https:\/\/doi.org\/10.1016\/j.clinthera.2013.07.430.","DOI":"10.1016\/j.clinthera.2013.07.430"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_038","doi-asserted-by":"crossref","unstructured":"Kim, GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 2004;24:595\u2013605. https:\/\/doi.org\/10.1159\/000082314.","DOI":"10.1159\/000082314"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_039","doi-asserted-by":"crossref","unstructured":"Kalaitzidis, R, Bakris, G. Should nephrologists use beta-blockers? A perspective. Nephrol Dial Transplant 2008;24:701\u20132. https:\/\/doi.org\/10.1093\/ndt\/gfn695.","DOI":"10.1093\/ndt\/gfn695"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_040","doi-asserted-by":"crossref","unstructured":"Simon, P, Ramee, MP, Boulahrouz, R, Stanescu, C, Charasse, C, Seng Ang, K, et al.. Epidemiologic data of primary glomerular diseases in western France. Kidney Int 2004;66:905\u20138. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00834.x.","DOI":"10.1111\/j.1523-1755.2004.00834.x"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_041","doi-asserted-by":"crossref","unstructured":"Chadban, SJ, Briganti, EM, Kerr, PG, Dunstan, DW, Welborn, TA, Zimmet, PZ, et al.. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 2003;14:(suppl_2):S131\u20138. https:\/\/doi.org\/10.1097\/01.asn.0000070152.11927.4a.","DOI":"10.1097\/01.ASN.0000070152.11927.4A"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_042","doi-asserted-by":"crossref","unstructured":"Sarnak, MJ, Levey, AS, Schoolwerth, AC, Coresh, J, Culleton, B, Hamm, LL, et al.. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical ardiology, and Epidemiology and Prevention. Circulation 2003;108:2154\u201369. https:\/\/doi.org\/10.1161\/01.cir.0000095676.90936.80.","DOI":"10.1161\/01.CIR.0000095676.90936.80"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_043","doi-asserted-by":"crossref","unstructured":"Boi, R, Ebefors, K, Nystr\u00f6m, J. The role of the mesangium in glomerular function. Acta Physiol 2023;239:e14045. https:\/\/doi.org\/10.1111\/apha.14045.","DOI":"10.1111\/apha.14045"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_044","doi-asserted-by":"crossref","unstructured":"Stai, S, Lioulios, G, Christodoulou, M, Papagianni, A, Stangou, M. From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years? J Nephrol 2022;36:551\u201361. https:\/\/doi.org\/10.1007\/s40620-022-01493-9.","DOI":"10.1007\/s40620-022-01493-9"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_045","doi-asserted-by":"crossref","unstructured":"Wall, SM. Regulation of blood pressure and salt balance by Pendrin-positive intercalated cells: Donald Seldin Lecture 2020. Hypertension 2022;79:706\u201316. https:\/\/doi.org\/10.1161\/hypertensionaha.121.16492.","DOI":"10.1161\/HYPERTENSIONAHA.121.16492"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_046","doi-asserted-by":"crossref","unstructured":"Chen, M, Wang, HY, Li, H, Li, XW, Li, XY, Chen, JH, et al.. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci 2010;339:233\u20138. https:\/\/doi.org\/10.1097\/maj.0b013e3181ca3a7d.","DOI":"10.1097\/MAJ.0b013e3181ca3a7d"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_047","doi-asserted-by":"crossref","unstructured":"Igarashi, P, Somlo, S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002;13:2384\u201398. https:\/\/doi.org\/10.1097\/01.asn.0000028643.17901.42.","DOI":"10.1097\/01.ASN.0000028643.17901.42"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_048","doi-asserted-by":"crossref","unstructured":"Rossetti, S, Harris, PC. Genotype\u2013phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2007;18:1374\u201380. https:\/\/doi.org\/10.1681\/asn.2007010125.","DOI":"10.1681\/ASN.2007010125"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_049","doi-asserted-by":"crossref","unstructured":"Yoder, BK. Role of primary cilia in the pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2007;18:1381\u20138. https:\/\/doi.org\/10.1681\/asn.2006111215.","DOI":"10.1681\/ASN.2006111215"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_050","doi-asserted-by":"crossref","unstructured":"Torres, VE, Chapman, AB, Devuyst, O, Gansevoort, RT, Grantham, JJ, Higashihara, E, et al.. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407\u201318. https:\/\/doi.org\/10.1056\/nejmoa1205511.","DOI":"10.1056\/NEJMoa1205511"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_051","doi-asserted-by":"crossref","unstructured":"Irazabal, MV, Rangel, LJ, Bergstralh, EJ, Osborn, SL, Harmon, AJ, Sundsbak, JL, et al.. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015;26:160\u201372. https:\/\/doi.org\/10.1681\/asn.2013101138.","DOI":"10.1681\/ASN.2013101138"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_052","doi-asserted-by":"crossref","unstructured":"Rossert, J. Drug-induced acute interstitial nephritis. Kidney Int 2001;60:804\u201317. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.060002804.x.","DOI":"10.1046\/j.1523-1755.2001.060002804.x"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_053","doi-asserted-by":"crossref","unstructured":"Huang, J, Gretz, N, Weinfurter, S. Filtration markers and determination methods for the assessment of kidney function. Eur J Pharmacol 2016;790:92\u20138. https:\/\/doi.org\/10.1016\/j.ejphar.2016.06.060.","DOI":"10.1016\/j.ejphar.2016.06.060"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_054","doi-asserted-by":"crossref","unstructured":"Tiong, HY, Huang, P, Xiong, S, Li, Y, Vathsala, A, Zink, D. Drug-induced nephrotoxicity: clinical impact and preclinical in\u00a0vitro models. Mol Pharm 2014;11:1933\u201348. https:\/\/doi.org\/10.1021\/mp400720w.","DOI":"10.1021\/mp400720w"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_055","doi-asserted-by":"crossref","unstructured":"Coca, SG, Singanamala, S, Parikh, CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012;81:442\u20138. https:\/\/doi.org\/10.1038\/ki.2011.379.","DOI":"10.1038\/ki.2011.379"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_056","doi-asserted-by":"crossref","unstructured":"Lopez-Novoa, JM, Quiros, Y, Vicente, L, Morales, AI, Lopez-Hernandez, FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79:33\u201345. https:\/\/doi.org\/10.1038\/ki.2010.337.","DOI":"10.1038\/ki.2010.337"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_057","doi-asserted-by":"crossref","unstructured":"Choudhury, D, Ahmed, Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006;2:80\u201391. https:\/\/doi.org\/10.1038\/ncpneph0076.","DOI":"10.1038\/ncpneph0076"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_058","doi-asserted-by":"crossref","unstructured":"Bonventre, JV. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant 2009;24:3265\u20138. https:\/\/doi.org\/10.1093\/ndt\/gfp010.","DOI":"10.1093\/ndt\/gfp010"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_059","doi-asserted-by":"crossref","unstructured":"Gursoy, V, Ozkalemkas, F, Ozkocaman, V, Serenli Yegen, Z, Ethem Pinar, I, Ener, B, et al.. Conventional amphotericin B associated nephrotoxicity in patients with hematologic malignancies. Cureus 2021. https:\/\/doi.org\/10.7759\/cureus.16445. https:\/\/www.cureus.com\/articles\/62752-conventional-amphotericin-b-associated-nephrotoxicity-in-patients-with-hematologic-malignancies [Accesed 6 Feb 2024].","DOI":"10.7759\/cureus.16445"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_060","doi-asserted-by":"crossref","unstructured":"Yao, X, Panichpisal, K, Kurtzman, N, Nugent, K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334:115\u201324. https:\/\/doi.org\/10.1097\/maj.0b013e31812dfe1e.","DOI":"10.1097\/MAJ.0b013e31812dfe1e"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_061","doi-asserted-by":"crossref","unstructured":"Miller, RP, Tadagavadi, RK, Ramesh, G, Reeves, WB. Mechanisms of cisplatin nephrotoxicity. Toxins 2010;2:2490\u2013518. https:\/\/doi.org\/10.3390\/toxins2112490.","DOI":"10.3390\/toxins2112490"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_062","doi-asserted-by":"crossref","unstructured":"Semenza, GL. Clinical investigation of hypoxia-inducible factors: getting there. J Clin Investig 2024;134:e176253. https:\/\/doi.org\/10.1172\/jci176253.","DOI":"10.1172\/JCI176253"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_063","unstructured":"Ghane Shahrbaf, F, Assadi, F. Drug-induced renal disorders. Drug-Induc Ren Disord 2015. Available from: https:\/\/doi.org\/10.12861\/jrip.2015.12 [Accesed 6 Feb 2024]."},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_064","doi-asserted-by":"crossref","unstructured":"Wargo, KA, Edwards, JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract 2014;27:573\u20137. https:\/\/doi.org\/10.1177\/0897190014546836.","DOI":"10.1177\/0897190014546836"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_065","doi-asserted-by":"crossref","unstructured":"El Mouedden, M. Gentamicin-induced apoptosis in renal cell lines and embryonic rat fibroblasts. Toxicol Sci 2000;56:229\u201339. https:\/\/doi.org\/10.1093\/toxsci\/56.1.229.","DOI":"10.1093\/toxsci\/56.1.229"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_066","doi-asserted-by":"crossref","unstructured":"Brewster, UC, Perazella, MA. A review of chronic lead intoxication: an unrecognized cause of chronic kidney disease. Am J Med Sci 2004;327:341\u20137. https:\/\/doi.org\/10.1097\/00000441-200406000-00008.","DOI":"10.1097\/00000441-200406000-00008"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_067","doi-asserted-by":"crossref","unstructured":"Mistro, S, Maciel, IDM, De Menezes, RG, Maia, ZP, Schooley, RT, Badaro, R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis 2012;54:1774\u20137. https:\/\/doi.org\/10.1093\/cid\/cis290.","DOI":"10.1093\/cid\/cis290"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_068","doi-asserted-by":"crossref","unstructured":"Izzedine, H, Hulot, JS, Launay-Vacher, V, Marcellini, P, Hadziyannis, SJ, Currie, G, et al.. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:1153\u20138. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00866.x.","DOI":"10.1111\/j.1523-1755.2004.00866.x"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_069","doi-asserted-by":"crossref","unstructured":"Herlitz, LC, Mohan, S, Stokes, MB, Radhakrishnan, J, D\u2019Agati, VD, Markowitz, GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010;78:1171\u20137. https:\/\/doi.org\/10.1038\/ki.2010.318.","DOI":"10.1038\/ki.2010.318"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_070","doi-asserted-by":"crossref","unstructured":"Fernandez-Fernandez, B, Montoya-Ferrer, A, Sanz, AB, Sanchez-Ni\u00f1o, MD, Izquierdo, MC, Poveda, J, et al.. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011;2011:1\u201311. https:\/\/doi.org\/10.1155\/2011\/354908.","DOI":"10.1155\/2011\/354908"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_071","doi-asserted-by":"crossref","unstructured":"Jafari, A, Khalili, H, Dashti-Khavidaki, S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol 2014;70:1029\u201340. https:\/\/doi.org\/10.1007\/s00228-014-1712-z.","DOI":"10.1007\/s00228-014-1712-z"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_072","doi-asserted-by":"crossref","unstructured":"Colpart, P, F\u00e9lix, S. N\u00e9phropathie cristalline secondaire au m\u00e9thotrexate : une entit\u00e9 rarement objectiv\u00e9e sur biopsie r\u00e9nale. Ann Pathol 2019;39:18\u201323. https:\/\/doi.org\/10.1016\/j.annpat.2018.08.005.","DOI":"10.1016\/j.annpat.2018.08.005"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_073","doi-asserted-by":"crossref","unstructured":"Praga, M, Gonz\u00e1lez, E. Acute interstitial nephritis. Kidney Int 2010;77:956\u201361. https:\/\/doi.org\/10.1038\/ki.2010.89.","DOI":"10.1038\/ki.2010.89"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_074","doi-asserted-by":"crossref","unstructured":"Tchounwou, PB, Yedjou, CG, Patlolla, AK, Sutton, DJ. Heavy metal toxicity and the environment. In: Luch, A, editor. Molecular, clinical and environmental toxicology. Basel: Springer Basel; 2012:133\u201364 pp. (Experientia Supplementum; vol. 101. http:\/\/link.springer.com\/10.1007\/978-3-7643-8340-4_6 [Accessed 7 Feb 2024].","DOI":"10.1007\/978-3-7643-8340-4_6"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_075","doi-asserted-by":"crossref","unstructured":"Lentini, P, Zanoli, L, Granata, A, Signorelli, SS, Castellino, P, Dellaquila, R. Kidney and heavy metals - the role of environmental exposure. Mol Med Rep 2017;15:3413\u20139. https:\/\/doi.org\/10.3892\/mmr.2017.6389.","DOI":"10.3892\/mmr.2017.6389"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_076","doi-asserted-by":"crossref","unstructured":"Werner, TT, Mudd, GM, Jowitt, SM, Huston, D. Rhenium mineral resources: a global assessment. Resour Policy 2023;82:103441. https:\/\/doi.org\/10.1016\/j.resourpol.2023.103441.","DOI":"10.1016\/j.resourpol.2023.103441"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_077","doi-asserted-by":"crossref","unstructured":"Satarug, S, Baker, JR, Urbenjapol, S, Haswell-Elkins, M, Reilly, PEB, Williams, DJ, et al.. A global perspective on cadmium pollution and toxicity in non-occupationally exposed population. Toxicol Lett 2003;137:65\u201383. https:\/\/doi.org\/10.1016\/s0378-4274(02)00381-8.","DOI":"10.1016\/S0378-4274(02)00381-8"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_078","doi-asserted-by":"crossref","unstructured":"Flora, SJS, Saxena, G, Gautam, P, Kaur, P, Gill, KD. Response of lead-induced oxidative stress and alterations in biogenic amines in different rat brain regions to combined administration of DMSA and MiADMSA. Chem Biol Interact 2007;170:209\u201320. https:\/\/doi.org\/10.1016\/j.cbi.2007.08.003.","DOI":"10.1016\/j.cbi.2007.08.003"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_079","doi-asserted-by":"crossref","unstructured":"Granata, A, Zanoli, L, Insalaco, M, Valentino, M, Pavlica, P, Di Nicol\u00f2, PP, et al.. Contrast-enhanced ultrasound (CEUS) in nephrology: has the\u00a0time come for its widespread use? Clin Exp Nephrol 2015;19:606\u201315. https:\/\/doi.org\/10.1007\/s10157-014-1040-8.","DOI":"10.1007\/s10157-014-1040-8"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_080","doi-asserted-by":"crossref","unstructured":"Neer, RM, Arnaud, CD, Zanchetta, JR, Prince, R, Gaich, GA, Reginster, JY, et al.. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434\u201341. https:\/\/doi.org\/10.1056\/nejm200105103441904.","DOI":"10.1097\/00006254-200110000-00018"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_081","doi-asserted-by":"crossref","unstructured":"Roberts, EA, Schilsky, ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089\u2013111. https:\/\/doi.org\/10.1002\/hep.22261.","DOI":"10.1002\/hep.22261"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_082","doi-asserted-by":"crossref","unstructured":"Debelle, FD, Vanherweghem, JL, Nortier, JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008;74:158\u201369. https:\/\/doi.org\/10.1038\/ki.2008.129.","DOI":"10.1038\/ki.2008.129"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_083","doi-asserted-by":"crossref","unstructured":"Jacob, S, H\u00e9ry, M, Protois, JC, Rossert, J, Stengel, B. Effect of organic solvent exposure on chronic kidney disease progression: the GN-PROGRESS cohort study. J Am Soc Nephrol 2007;18:274\u201381. https:\/\/doi.org\/10.1681\/ASN.2006060652.","DOI":"10.1681\/ASN.2006060652"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_084","doi-asserted-by":"crossref","unstructured":"Hsueh, YM, Chung, CJ, Shiue, HS, Chen, JB, Chiang, SS, Yang, MH, et al.. Urinary arsenic species and CKD in a Taiwanese population: a case-control study. Am J Kidney Dis 2009;54:859\u201370. https:\/\/doi.org\/10.1053\/j.ajkd.2009.06.016.","DOI":"10.1053\/j.ajkd.2009.06.016"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_085","doi-asserted-by":"crossref","unstructured":"Singh, J, Jain, A, Bhamra, R, Rathi, V, Dhingra, AK. The mechanistic role of different mediators in the pathophysiology ofNephropathy: a review. Curr Drug Targets 2023;24:104\u201317. https:\/\/doi.org\/10.2174\/1389450124666221026152647.","DOI":"10.2174\/1389450124666221026152647"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_086","doi-asserted-by":"crossref","unstructured":"Kurts, C, Panzer, U, Anders, HJ, Rees, AJ. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol 2013;13:738\u201353. https:\/\/doi.org\/10.1038\/nri3523.","DOI":"10.1038\/nri3523"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_087","doi-asserted-by":"crossref","unstructured":"Lech, M, Anders, HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013;24:1357\u201366. https:\/\/doi.org\/10.1681\/asn.2013010026.","DOI":"10.1681\/ASN.2013010026"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_088","doi-asserted-by":"crossref","unstructured":"Kiryluk, K, Novak, J. The genetics and immunobiology of IgA nephropathy. J Clin Investig 2014;124:2325\u201332. https:\/\/doi.org\/10.1172\/jci74475.","DOI":"10.1172\/JCI74475"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_089","doi-asserted-by":"crossref","unstructured":"Kumar, D, Singla, SK, Puri, V, Puri, S. The restrained expression of NF-kB in renal tissue ameliorates folic acid induced acute kidney injury in mice. PLoS One 2015;10:e115947. https:\/\/doi.org\/10.1371\/journal.pone.0115947.","DOI":"10.1371\/journal.pone.0115947"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_090","doi-asserted-by":"crossref","unstructured":"Roberts, ISD. Pathology of IgA nephropathy. Nat Rev Nephrol 2014;10:445\u201354. https:\/\/doi.org\/10.1038\/nrneph.2014.92.","DOI":"10.1038\/nrneph.2014.92"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_091","doi-asserted-by":"crossref","unstructured":"Danilewicz, M, W\u0105growska-Danilewicz, M. Tubular NF-\u03baB is overexpressed in proteinuric patients with IgA nephropathy. Folia Histochem Cytobiol 2012;50:93\u20138. https:\/\/doi.org\/10.5603\/fhc.2012.0013.","DOI":"10.5603\/FHC.2012.0013"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_092","doi-asserted-by":"crossref","unstructured":"Tsai, YL, Hua, KF, Chen, A, Wei, CW, Chen, WS, Wu, CY, et al.. NLRP3 inflammasome: pathogenic role and potential therapeutic target for IgA nephropathy. Sci Rep 2017;7:41123. https:\/\/doi.org\/10.1038\/srep41123.","DOI":"10.1038\/srep41123"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_093","doi-asserted-by":"crossref","unstructured":"Wu, M, Han, W, Song, S, Du, Y, Liu, C, Chen, N, et al.. NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice. Mol Cell Endocrinol 2018;478:115\u201325. https:\/\/doi.org\/10.1016\/j.mce.2018.08.002.","DOI":"10.1016\/j.mce.2018.08.002"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_094","doi-asserted-by":"crossref","unstructured":"Feng, H, Gu, J, Gou, F, Huang, W, Gao, C, Chen, G, et al.. High glucose and lipopolysaccharide prime NLRP3 inflammasome via ROS\/TXNIP pathway in mesangial cells. J Diabetes Res 2016;2016:1\u201311. https:\/\/doi.org\/10.1155\/2016\/6973175.","DOI":"10.1155\/2016\/6973175"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_095","doi-asserted-by":"crossref","unstructured":"Lech, M, Lorenz, G, Kulkarni, OP, Grosser, MOO, Stigrot, N, Darisipudi, MN, et al.. NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-\u03b2 receptor signalling. Ann Rheum Dis 2015;74:2224\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205496.","DOI":"10.1136\/annrheumdis-2014-205496"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_096","doi-asserted-by":"crossref","unstructured":"Zhao, J, Wang, H, Dai, C, Wang, H, Zhang, H, Huang, Y, et al.. P2X 7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3\/ASC\/caspase 1 pathway. Arthritis Rheum 2013;65:3176\u201385. https:\/\/doi.org\/10.1002\/art.38174.","DOI":"10.1002\/art.38174"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_097","doi-asserted-by":"crossref","unstructured":"Martinon, F, Burns, K, Tschopp, J. The inflammasome. Mol Cell 2002;10:417\u201326. https:\/\/doi.org\/10.1016\/s1097-2765(02)00599-3.","DOI":"10.1016\/S1097-2765(02)00599-3"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_098","doi-asserted-by":"crossref","unstructured":"Krakauer, T. Inflammasomes, autophagy, and cell death: the trinity of innate host defense against intracellular bacteria. Mediat Inflamm 2019;2019:1\u201310. https:\/\/doi.org\/10.1155\/2019\/2471215.","DOI":"10.1155\/2019\/2471215"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_099","doi-asserted-by":"crossref","unstructured":"Chun, J, Chung, H, Wang, X, Barry, R, Taheri, ZM, Platnich, JM, et al.. NLRP3 localizes to the tubular epithelium in human kidney and correlates with outcome in IgA nephropathy. Sci Rep 2016;6:24667. https:\/\/doi.org\/10.1038\/srep24667.","DOI":"10.1038\/srep24667"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_100","doi-asserted-by":"crossref","unstructured":"Garibotto, G, Carta, A, Picciotto, D, Viazzi, F, Verzola, D. Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy. J Nephrol 2017;30:719\u201327. https:\/\/doi.org\/10.1007\/s40620-017-0432-8.","DOI":"10.1007\/s40620-017-0432-8"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_101","doi-asserted-by":"crossref","unstructured":"Bai, Y, Tong, Y, Liu, Y, Hu, H. Self-dsDNA in the pathogenesis of systemic lupus erythematosus. Clin Exp Immunol 2017;191:1\u201310. https:\/\/doi.org\/10.1111\/cei.13041.","DOI":"10.1111\/cei.13041"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_102","doi-asserted-by":"crossref","unstructured":"Li, X, Guo, X, Liu, H, Gao, G, Xu, G, Fei, X, et al.. Skin inflammation induced by lupus serum was inhibited in IL-1R deficient mice. Clin Immunol 2017;180:63\u20138. https:\/\/doi.org\/10.1016\/j.clim.2017.03.015.","DOI":"10.1016\/j.clim.2017.03.015"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_103","doi-asserted-by":"crossref","unstructured":"Usmani, S, Ahmad, M, Sahabjada, HA, Arshad, M, Ali, M. Cellular oxidative stress and antiproliferative effects of Cordia dichotoma (Linn.) seeds extract and their fractions on human cervix epitheloid (HeLa) and human lung (A549) carcinoma cells. Eur J Integr Med 2018;21:1\u201310. https:\/\/doi.org\/10.1016\/j.eujim.2018.05.014.","DOI":"10.1016\/j.eujim.2018.05.014"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_104","doi-asserted-by":"crossref","unstructured":"McSweeney, KR, Gadanec, LK, Qaradakhi, T, Ali, BA, Zulli, A, Apostolopoulos, V. Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers 2021;13:1572. https:\/\/doi.org\/10.3390\/cancers13071572.","DOI":"10.3390\/cancers13071572"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_105","doi-asserted-by":"crossref","unstructured":"Galluzzi, L, Vitale, I, Aaronson, SA, Abrams, JM, Adam, D, Agostinis, P, et al.. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 2018;25:486\u2013541. https:\/\/doi.org\/10.1038\/s41418-017-0012-4.","DOI":"10.1038\/s41418-018-0102-y"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_106","doi-asserted-by":"crossref","unstructured":"Zhou, X, Xu, C, Dong, J, Liao, L. Role of renal tubular programed cell death in diabetic kidney disease. Diabetes Metab Res Rev 2023;39:e3596. https:\/\/doi.org\/10.1002\/dmrr.3596.","DOI":"10.1002\/dmrr.3596"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_107","doi-asserted-by":"crossref","unstructured":"Sanz, AB, Sanchez-Ni\u00f1o, MD, Ramos, AM, Ortiz, A. Regulated cell death pathways in kidney disease. Nat Rev Nephrol 2023;19:281\u201399. https:\/\/doi.org\/10.1038\/s41581-023-00694-0.","DOI":"10.1038\/s41581-023-00694-0"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_108","doi-asserted-by":"crossref","unstructured":"Erekat, NS. Programmed cell death in diabetic nephropathy: a review of apoptosis, autophagy, and necroptosis. Med Sci Monit 2022;28:937766. https:\/\/doi.org\/10.12659\/msm.937766.","DOI":"10.12659\/MSM.937766"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_109","doi-asserted-by":"crossref","unstructured":"Kowalski, S, Karska, J, \u0141api\u0144ska, Z, Hetna\u0142, B, Saczko, J, Kulbacka, J. An overview of programmed cell death: apoptosis and pyroptosis\u00a0\u2013 mechanisms, differences, and significance in organism physiology and pathophysiology. J Cell Biochem 2023;124:765\u201384. https:\/\/doi.org\/10.1002\/jcb.30413.","DOI":"10.1002\/jcb.30413"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_110","doi-asserted-by":"crossref","unstructured":"Adamczak, M, Ritz, E, Wiecek, A. Carbohydrate metabolism in chronic renal disease. In: Nutritional Management of renal disease. Elsevier; 2022:29\u201341 pp. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128185407000057.","DOI":"10.1016\/B978-0-12-818540-7.00005-7"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_111","doi-asserted-by":"crossref","unstructured":"Idris, S, Mishra, A, Khushtar, M. Phytochemical, ethanomedicinal and pharmacological applications of escin from Aesculus hippocastanum L . towards future medicine. J Basic Clin Physiol Pharmacol 2020;31:20190115. https:\/\/doi.org\/10.1515\/jbcpp-2019-0115.","DOI":"10.1515\/jbcpp-2019-0115"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_112","doi-asserted-by":"crossref","unstructured":"Kaur, G, Singh, N, Samuel, SS, Bora, HK, Sharma, S, Pachauri, SD, et al.. Withania somnifera shows a protective effect in monocrotaline-induced pulmonary hypertension. Pharm Biol 2015;53:147\u201357. https:\/\/doi.org\/10.3109\/13880209.2014.912240.","DOI":"10.3109\/13880209.2014.912240"},{"key":"2025121209213467726_j_jbcpp-2024-0220_ref_113","doi-asserted-by":"crossref","unstructured":"Ronco, C, Bellomo, R, Kellum, JA. Acute kidney injury. Lancet 2019;394:1949\u201364. https:\/\/doi.org\/10.1016\/s0140-6736(19)32563-2.","DOI":"10.1016\/S0140-6736(19)32563-2"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0220\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0220\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:18:16Z","timestamp":1765541896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0220\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":113,"journal-issue":{"issue":"2-3","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,5,30]]}},"alternative-id":["10.1515\/jbcpp-2024-0220"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2024-0220","relation":{},"ISSN":["2191-0286"],"issn-type":[{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}